Intrinsic value of Adamas Pharmaceuticals, Inc. - ADMS

Previous Close

$6.00

  Intrinsic Value

$0.78

stock screener

  Rating & Target

str. sell

-87%

Previous close

$6.00

 
Intrinsic value

$0.78

 
Up/down potential

-87%

 
Rating

str. sell

We calculate the intrinsic value of ADMS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  54
  84
  126
  182
  257
  354
  475
  623
  802
  1,013
  1,258
  1,538
  1,854
  2,206
  2,594
  3,018
  3,476
  3,969
  4,495
  5,053
  5,644
  6,266
  6,918
  7,602
  8,315
  9,059
  9,834
  10,640
  11,479
  12,350
Variable operating expenses, $m
  1,686
  2,605
  3,895
  5,652
  7,974
  10,962
  14,714
  19,320
  24,861
  31,401
  38,992
  47,672
  57,461
  68,367
  80,387
  93,509
  107,715
  122,981
  139,282
  156,595
  174,895
  194,165
  214,390
  235,560
  257,673
  280,730
  304,743
  329,727
  355,704
  382,704
Fixed operating expenses, $m
  74
  75
  77
  79
  80
  82
  84
  86
  88
  90
  91
  93
  96
  98
  100
  102
  104
  107
  109
  111
  114
  116
  119
  121
  124
  127
  130
  132
  135
  138
Total operating expenses, $m
  1,760
  2,680
  3,972
  5,731
  8,054
  11,044
  14,798
  19,406
  24,949
  31,491
  39,083
  47,765
  57,557
  68,465
  80,487
  93,611
  107,819
  123,088
  139,391
  156,706
  175,009
  194,281
  214,509
  235,681
  257,797
  280,857
  304,873
  329,859
  355,839
  382,842
Operating income, $m
  -1,705
  -2,596
  -3,847
  -5,548
  -7,797
  -10,690
  -14,323
  -18,783
  -24,146
  -30,477
  -37,825
  -46,227
  -55,702
  -66,258
  -77,893
  -90,594
  -104,343
  -119,119
  -134,896
  -151,652
  -169,365
  -188,016
  -207,590
  -228,080
  -249,482
  -271,798
  -295,038
  -319,219
  -344,360
  -370,492
EBITDA, $m
  -1,704
  -2,594
  -3,844
  -5,544
  -7,791
  -10,683
  -14,313
  -18,770
  -24,129
  -30,456
  -37,800
  -46,196
  -55,665
  -66,214
  -77,841
  -90,533
  -104,274
  -119,039
  -134,807
  -151,551
  -169,252
  -187,891
  -207,452
  -227,928
  -249,315
  -271,617
  -294,842
  -319,006
  -344,131
  -370,245
Interest expense (income), $m
  0
  20
  7
  14
  23
  36
  52
  73
  100
  133
  172
  219
  273
  335
  405
  482
  568
  662
  763
  872
  988
  1,111
  1,242
  1,379
  1,523
  1,674
  1,832
  1,996
  2,167
  2,345
  2,530
Earnings before tax, $m
  -1,726
  -2,603
  -3,860
  -5,571
  -7,832
  -10,742
  -14,397
  -18,883
  -24,279
  -30,649
  -38,044
  -46,500
  -56,037
  -66,663
  -78,375
  -91,162
  -105,005
  -119,882
  -135,768
  -152,640
  -170,476
  -189,258
  -208,970
  -229,603
  -251,156
  -273,630
  -297,034
  -321,386
  -346,706
  -373,022
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -1,726
  -2,603
  -3,860
  -5,571
  -7,832
  -10,742
  -14,397
  -18,883
  -24,279
  -30,649
  -38,044
  -46,500
  -56,037
  -66,663
  -78,375
  -91,162
  -105,005
  -119,882
  -135,768
  -152,640
  -170,476
  -189,258
  -208,970
  -229,603
  -251,156
  -273,630
  -297,034
  -321,386
  -346,706
  -373,022

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  77
  119
  178
  259
  365
  502
  673
  884
  1,138
  1,437
  1,785
  2,182
  2,630
  3,129
  3,680
  4,280
  4,930
  5,629
  6,375
  7,168
  8,006
  8,888
  9,813
  10,782
  11,795
  12,850
  13,949
  15,093
  16,282
  17,518
Adjusted assets (=assets-cash), $m
  77
  119
  178
  259
  365
  502
  673
  884
  1,138
  1,437
  1,785
  2,182
  2,630
  3,129
  3,680
  4,280
  4,930
  5,629
  6,375
  7,168
  8,006
  8,888
  9,813
  10,782
  11,795
  12,850
  13,949
  15,093
  16,282
  17,518
Revenue / Adjusted assets
  0.701
  0.706
  0.708
  0.703
  0.704
  0.705
  0.706
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
  0.705
Average production assets, $m
  5
  8
  13
  18
  26
  35
  47
  62
  80
  101
  126
  154
  185
  221
  259
  302
  348
  397
  449
  505
  564
  627
  692
  760
  832
  906
  983
  1,064
  1,148
  1,235
Working capital, $m
  -11
  -17
  -25
  -36
  -51
  -70
  -94
  -124
  -160
  -202
  -250
  -306
  -369
  -439
  -516
  -600
  -692
  -790
  -894
  -1,006
  -1,123
  -1,247
  -1,377
  -1,513
  -1,655
  -1,803
  -1,957
  -2,117
  -2,284
  -2,458
Total debt, $m
  42
  80
  133
  205
  301
  424
  579
  768
  997
  1,266
  1,579
  1,936
  2,340
  2,789
  3,284
  3,825
  4,410
  5,039
  5,710
  6,424
  7,178
  7,971
  8,805
  9,677
  10,588
  11,538
  12,527
  13,556
  14,626
  15,738
Total liabilities, $m
  69
  107
  160
  233
  328
  452
  606
  796
  1,024
  1,294
  1,606
  1,964
  2,367
  2,816
  3,312
  3,852
  4,437
  5,066
  5,738
  6,451
  7,205
  7,999
  8,832
  9,704
  10,615
  11,565
  12,554
  13,583
  14,654
  15,766
Total equity, $m
  8
  12
  18
  26
  36
  50
  67
  88
  114
  144
  178
  218
  263
  313
  368
  428
  493
  563
  638
  717
  801
  889
  981
  1,078
  1,179
  1,285
  1,395
  1,509
  1,628
  1,752
Total liabilities and equity, $m
  77
  119
  178
  259
  364
  502
  673
  884
  1,138
  1,438
  1,784
  2,182
  2,630
  3,129
  3,680
  4,280
  4,930
  5,629
  6,376
  7,168
  8,006
  8,888
  9,813
  10,782
  11,794
  12,850
  13,949
  15,092
  16,282
  17,518
Debt-to-equity ratio
  5.440
  6.700
  7.460
  7.940
  8.250
  8.450
  8.590
  8.690
  8.760
  8.810
  8.850
  8.870
  8.900
  8.910
  8.930
  8.940
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.980
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -1,726
  -2,603
  -3,860
  -5,571
  -7,832
  -10,742
  -14,397
  -18,883
  -24,279
  -30,649
  -38,044
  -46,500
  -56,037
  -66,663
  -78,375
  -91,162
  -105,005
  -119,882
  -135,768
  -152,640
  -170,476
  -189,258
  -208,970
  -229,603
  -251,156
  -273,630
  -297,034
  -321,386
  -346,706
  -373,022
Depreciation, amort., depletion, $m
  1
  2
  3
  4
  6
  7
  10
  13
  16
  21
  25
  31
  37
  44
  52
  60
  70
  79
  90
  101
  113
  125
  138
  152
  166
  181
  197
  213
  230
  247
Funds from operations, $m
  -1,724
  -2,601
  -3,857
  -5,567
  -7,827
  -10,735
  -14,387
  -18,870
  -24,262
  -30,629
  -38,019
  -46,469
  -56,000
  -66,619
  -78,323
  -91,102
  -104,935
  -119,802
  -135,678
  -152,539
  -170,364
  -189,132
  -208,831
  -229,451
  -250,989
  -273,448
  -296,838
  -321,173
  -346,476
  -372,775
Change in working capital, $m
  -4
  -6
  -8
  -11
  -15
  -19
  -24
  -30
  -36
  -42
  -49
  -56
  -63
  -70
  -77
  -84
  -91
  -98
  -105
  -111
  -118
  -124
  -130
  -136
  -142
  -148
  -154
  -160
  -167
  -173
Cash from operations, $m
  -1,720
  -2,595
  -3,849
  -5,556
  -7,812
  -10,716
  -14,363
  -18,840
  -24,227
  -30,587
  -37,971
  -46,414
  -55,937
  -66,549
  -78,246
  -91,017
  -104,844
  -119,704
  -135,574
  -152,428
  -170,246
  -189,008
  -208,701
  -229,315
  -250,847
  -273,300
  -296,684
  -321,012
  -346,309
  -372,602
Maintenance CAPEX, $m
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -12
  -16
  -20
  -25
  -31
  -37
  -44
  -52
  -60
  -70
  -79
  -90
  -101
  -113
  -125
  -138
  -152
  -166
  -181
  -197
  -213
  -230
New CAPEX, $m
  -2
  -3
  -4
  -6
  -7
  -10
  -12
  -15
  -18
  -21
  -24
  -28
  -32
  -35
  -39
  -42
  -46
  -49
  -53
  -56
  -59
  -62
  -65
  -68
  -71
  -74
  -77
  -81
  -84
  -87
Cash from investing activities, $m
  -3
  -4
  -6
  -9
  -11
  -15
  -19
  -24
  -30
  -37
  -44
  -53
  -63
  -72
  -83
  -94
  -106
  -119
  -132
  -146
  -160
  -175
  -190
  -206
  -223
  -240
  -258
  -278
  -297
  -317
Free cash flow, $m
  -1,723
  -2,599
  -3,855
  -5,564
  -7,823
  -10,731
  -14,382
  -18,865
  -24,257
  -30,624
  -38,015
  -46,467
  -55,999
  -66,621
  -78,329
  -91,112
  -104,950
  -119,823
  -135,706
  -152,574
  -170,406
  -189,184
  -208,892
  -229,522
  -251,071
  -273,541
  -296,942
  -321,290
  -346,606
  -372,919
Issuance/(repayment) of debt, $m
  -75
  38
  53
  72
  96
  123
  155
  190
  228
  269
  313
  358
  403
  449
  495
  541
  585
  629
  672
  713
  754
  794
  833
  872
  911
  950
  989
  1,029
  1,070
  1,112
Issuance/(repurchase) of shares, $m
  1,830
  2,608
  3,866
  5,579
  7,843
  10,756
  14,414
  18,904
  24,304
  30,679
  38,079
  46,540
  56,082
  66,713
  78,430
  91,222
  105,070
  119,952
  135,843
  152,720
  170,560
  189,346
  209,062
  229,700
  251,257
  273,735
  297,144
  321,500
  346,825
  373,146
Cash from financing (excl. dividends), $m  
  1,755
  2,646
  3,919
  5,651
  7,939
  10,879
  14,569
  19,094
  24,532
  30,948
  38,392
  46,898
  56,485
  67,162
  78,925
  91,763
  105,655
  120,581
  136,515
  153,433
  171,314
  190,140
  209,895
  230,572
  252,168
  274,685
  298,133
  322,529
  347,895
  374,258
Total cash flow (excl. dividends), $m
  31
  46
  64
  88
  116
  149
  187
  229
  275
  325
  377
  431
  486
  541
  596
  651
  705
  757
  809
  859
  908
  956
  1,003
  1,050
  1,097
  1,144
  1,191
  1,240
  1,289
  1,340
Retained Cash Flow (-), $m
  -1,830
  -2,608
  -3,866
  -5,579
  -7,843
  -10,756
  -14,414
  -18,904
  -24,304
  -30,679
  -38,079
  -46,540
  -56,082
  -66,713
  -78,430
  -91,222
  -105,070
  -119,952
  -135,843
  -152,720
  -170,560
  -189,346
  -209,062
  -229,700
  -251,257
  -273,735
  -297,144
  -321,500
  -346,825
  -373,146
Prev. year cash balance distribution, $m
  187
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -1,612
  -2,562
  -3,802
  -5,492
  -7,727
  -10,607
  -14,227
  -18,675
  -24,029
  -30,355
  -37,703
  -46,109
  -55,596
  -66,172
  -77,834
  -90,571
  -104,365
  -119,194
  -135,034
  -151,861
  -169,652
  -188,390
  -208,059
  -228,650
  -250,160
  -272,591
  -295,953
  -320,261
  -345,536
  -371,806
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -1,545
  -2,345
  -3,309
  -4,522
  -5,990
  -7,698
  -9,612
  -11,672
  -13,803
  -15,914
  -17,904
  -19,676
  -21,139
  -22,215
  -22,851
  -23,016
  -22,708
  -21,951
  -20,791
  -19,297
  -17,548
  -15,631
  -13,636
  -11,646
  -9,732
  -7,953
  -6,352
  -4,955
  -3,772
  -2,800
Current shareholders' claim on cash, %
  50.0
  0.3
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

FINANCIAL RATIOS  of  Adamas Pharmaceuticals, Inc. (ADMS)

Valuation Ratios
P/E Ratio -2.2
Price to Sales 132.1
Price to Book 1
Price to Tangible Book
Price to Cash Flow -2.8
Price to Free Cash Flow -2.6
Growth Rates
Sales Growth Rate -50%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 100%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0.1
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -44.3%
Ret/ On Assets - 3 Yr. Avg. -24%
Return On Total Capital -48.4%
Ret/ On T. Cap. - 3 Yr. Avg. -26.3%
Return On Equity -48.4%
Return On Equity - 3 Yr. Avg. -26.3%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -5900%
EBITDA Margin - 3 Yr. Avg. -2906%
Operating Margin -6100%
Oper. Margin - 3 Yr. Avg. -2972%
Pre-Tax Margin -6000%
Pre-Tax Margin - 3 Yr. Avg. -2939.3%
Net Profit Margin -6000%
Net Profit Margin - 3 Yr. Avg. -2860.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 17.7%
Payout Ratio 0%

ADMS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ADMS stock intrinsic value calculation we used $34 million for the last fiscal year's total revenue generated by Adamas Pharmaceuticals, Inc.. The default revenue input number comes from 0001 income statement of Adamas Pharmaceuticals, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ADMS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ADMS is calculated based on our internal credit rating of Adamas Pharmaceuticals, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Adamas Pharmaceuticals, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ADMS stock the variable cost ratio is equal to 3100%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $72 million in the base year in the intrinsic value calculation for ADMS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 17.3% for Adamas Pharmaceuticals, Inc..

Corporate tax rate of 27% is the nominal tax rate for Adamas Pharmaceuticals, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ADMS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ADMS are equal to 10%.

Life of production assets of 2.3 years is the average useful life of capital assets used in Adamas Pharmaceuticals, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ADMS is equal to -19.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $89.885 million for Adamas Pharmaceuticals, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 27.449 million for Adamas Pharmaceuticals, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Adamas Pharmaceuticals, Inc. at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
ACOR Acorda Therape 6.62 1.03  str.sell
ACAD ACADIA Pharmac 27.23 4.99  str.sell
MRK Merck & Compan 79.73 44.01  sell
GSK GlaxoSmithKlin 40.42 65.66  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.